Aurinia Q2 2023 Earnings Report
Key Takeaways
Aurinia Pharmaceuticals reported a strong second quarter in 2023, with net revenue increasing to $41.5 million, a 47% increase compared to the prior year. The company is increasing its full-year revenue guidance to $150 - $160 million for net product sales of LUPKYNIS.
Net revenue for Q2 2023 increased to $41.5 million, a 47% increase year-over-year.
The company is increasing its full year 2023 revenue guidance to $150 - $160 million from net product sales of LUPKYNIS.
There were approximately 1,911 patients on LUPKYNIS therapy as of June 30, 2023, a 50% increase year-over-year.
Aurinia added 451 patient start forms (PSFs) during Q2 2023, a 10% increase over the previous year.
Aurinia
Aurinia
Aurinia Revenue by Segment
Forward Guidance
The Company is increasing its net product revenue guidance to a range of $150 - $160 million for net product sales of LUPKYNIS.
Positive Outlook
- Guidance range is based on assumptions regarding PSF run rates.
- Consistent conversion rates.
- Time to convert.
- Persistency.
- Pricing.